Search results for "VENOUS THROMBOSIS"

showing 10 items of 183 documents

Haemorheological profile in congenital afibrinogenemia and in congenital dysfibrinogenemia: A clinical case report

2019

Although the inherited quantitative and qualitative disorders of fibrinogen are rare, in the course of time patients may develop complications including episodes of arterial and venous thrombosis. It can be useful to complete the laboratory assessment of these clinical conditions with the evaluation of the haemorheological profile. The data obtained from this study showed that congenital afibrinogenemia was characterized by a primary plasma hypoviscosity, whereas congenital dysfibrinogenemia by a primary plasma hyperviscosity. Both these haemorheological alterations may concur, with different mechanisms, to the pathogenesis of thrombotic vascular complications.

AdultMaleHypoviscosityPediatricsmedicine.medical_specialtyPhysiologyHyperviscosity030204 cardiovascular system & hematologyFibrinogen030218 nuclear medicine & medical imagingYoung Adult03 medical and health sciences0302 clinical medicinePhysiology (medical)medicineHumansAfibrinogenemiabusiness.industryCongenital dysfibrinogenemiaFibrinogenHematologyMiddle AgedAfibrinogenemiamedicine.diseaseCongenital afibrinogenemiaVenous thrombosisFemaleClinical caseCardiology and Cardiovascular MedicinebusinessHumanmedicine.drugClinical Hemorheology and Microcirculation
researchProduct

Deep Venous Thrombosis: Leukocyte Rheology at Baseline and after in vitro Activation

2001

We evaluated leukocyte rheology, expressed as leukocyte filtration, polymorphonuclear (PMN) membrane fluidity and cytosolic Ca<sup>2+</sup> concentration in subjects with acute deep venous leg thrombosis (DVT). In 14 subjects with leg DVT we examined the leukocyte filtration [unfractionated, mononuclear cells (MN), PMNs], PMN membrane fluidity and PMN cytosolic Ca<sup>2+</sup> concentration. Subsequently, we evaluated the same PMN variables after in vitro chemotactic activation with 4-phorbol-12-myristate-13-acetate. At baseline, we observed a significant difference in the filtration of unfractionated and MNs and in PMN cytosolic Ca<sup>2+</sup> concentra…

AdultMalePathologymedicine.medical_specialtyMembrane FluidityNeutrophileDeep veinBiologyGranulocytePathogenesisPhysiology (medical)LeukocytesmedicineMembrane fluidityHumansCells CulturedAgedVascular diseaseHematologyMiddle AgedThrombophlebitismedicine.diseaseThrombosisChemotaxis LeukocyteVenous thrombosismedicine.anatomical_structureImmunologyCalciumFemaleRheologyPathophysiology of Haemostasis and Thrombosis
researchProduct

Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer

2008

Limited information exists on the incidence of symptomatic venous thromboembolism (vTE) in patients undergoing chest surgery for lung cancer. Several factors increase the thromboembolic risk in patients undergoing surgery for lung cancer: the intrinsic procoagulant effect of cancer,extensive surgical intervention, dependent limb position in the operating room, and vessel injury consequent to the operation. Furthermore,these patients might be especially vulnerable to pulmonary embolism (PE) because of the loss of lung tissue and the presence of chronic obstructive pulmonary disease and cardiovascular diseases caused by smoking.t Older studies found a very high incidence of thromboembolic eve…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentSeverity of Illness Indexvenous thromboembolism thoracotomySettore MED/15 - Malattie Del SangueCohort StudiesAge DistributionPostoperative ComplicationsRisk FactorsmedicineHumansMulticenter Studies as TopicThoracotomySex DistributionLung cancerPneumonectomyAgedNeoplasm StagingRetrospective StudiesAged 80 and overOntariobusiness.industryVascular diseaseIncidence (epidemiology)IncidenceRespiratory diseaseCancerAnticoagulantsRetrospective cohort studyVenous ThromboembolismMiddle Agedmedicine.diseasePrognosisSurvival AnalysisSurgeryVenous thrombosisItalyThoracotomyFemaleSurgerybusinessPulmonary EmbolismCardiology and Cardiovascular MedicineThe Journal of Thoracic and Cardiovascular Surgery
researchProduct

Thromboembolic events in Fabry disease and the impact of factor V Leiden

2015

Although several reports suggest an increased thromboembolic event rate, especially regarding strokes and TIAs at early age in patients with Fabry disease (FD), the risk for patients with FD to experience these events, the clinical relevance of additional risk factors including the concurrence of factor V Leiden (FVL), and the benefit of enzyme replacement therapy (ERT) regarding these events remain unclear.Three hundred four consecutively recruited patients with FD were evaluated for their lifetime occurrence of thromboembolic events such as stroke, TIA, deep vein thrombosis, and pulmonary embolism. The thromboembolic risk was determined in patients with FD and concurrent FVL, and the impa…

AdultMaleRiskmedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismDeep veinComorbidityBiochemistryYoung AdultEndocrinologyInternal medicineGeneticsmedicineFactor V LeidenHumansEnzyme Replacement TherapyChildMolecular BiologyStrokeAgedAged 80 and overVenous Thrombosisbusiness.industryHazard ratioFactor VEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseThrombosisComorbidityPulmonary embolismStrokemedicine.anatomical_structureIschemic Attack TransientChild PreschoolFabry DiseaseFemaleNeurology (clinical)Pulmonary EmbolismbusinessNeurology
researchProduct

Deferral of assessment of pulmonary embolism

2007

We evaluated a simplified algorithm for safely postponing diagnostic imaging for pulmonary embolism (PE). At the index visit, patients were identified as being at high or low risk of PE; the former received full dosage low molecular weight heparin while the latter were left untreated until performance of diagnostic imaging (max 72 hours). During this period, no thromboembolic events occurred in low-risk patients (0/211, 0.% [upper 95% CI 0.9%]); only one event occurred in those at high-risk (1/125, 0.8% [upper 95% CI, 1.2]). Our study demonstrates that diagnostic imaging for PE can be safely deferred for up to 3 days.

AdultMaleRiskmedicine.medical_specialtyTime Factorsmedicine.drug_classLow molecular weight heparinThrombophiliaVentilation/perfusion ratioFibrin Fibrinogen Degradation ProductsPredictive Value of TestsThromboembolismD-dimerPrevalenceVentilation-Perfusion RatiomedicineHumansThrombophiliaAgedAged 80 and overVenous Thrombosisbusiness.industryRespiratory diseaseAnticoagulantsHematologyMiddle Agedmedicine.diseasePulmonary embolismSurgeryHospitalizationVenous thrombosisEarly DiagnosisTreatment OutcomePredictive value of testsFemalePulmonary EmbolismbusinessTomography Spiral ComputedAlgorithmsHaematologica
researchProduct

Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study.

2009

summaryKnowledge on the natural history of mesenteric vein thrombosis (MVT) and of the efficacy and safety of long-term oral anticoagulant therapy (OAT) in this setting is based on small uncontrolled series of patients with a limited follow-up. It was the aim of the study to assess the natural history of MVT in a cohort of patients treated with OAT. The charts of all MVT patients currently attending or who have attended four anticoagulation clinics were reviewed. Information on risk factors, treatment, recurrence, major bleeding and mortality was collected. Seventyseven patients (mean age 49.2 years; 45 males) were included with a median follow-up of 36 months (range 2–204 months). Forty-si…

AdultMaleRiskmedicine.medical_specialtyVitamin Kmedicine.drug_classmedicine.medical_treatmentSettore MED/15 - Malattie Del SangueCohort StudiesRisk FactorsmedicineHumansVeinAgedRetrospective StudiesAged 80 and overVenous ThrombosisChemotherapybusiness.industryAnticoagulantAnticoagulantsRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseSurgeryMesenteric ArteriesNatural historyVenous thrombosismedicine.anatomical_structuremesenteric vein thrombosisCohortFemalebusinessCohort study
researchProduct

Late seizures in cerebral venous thrombosis

2020

ObjectiveTo examine the incidence, characteristics, treatment, and predictors of late seizures (LS) after cerebral venous thrombosis (CVT), we described these features in a registry of 1,127 patients with CVT.MethodsWe included consecutive adult patients from an international consortium of 12 hospital-based CVT registries. We excluded patients with a history of epilepsy or with <8 days of follow-up. We defined LS as seizures occurring >7 days after diagnosis of CVT. We used multivariable Cox regression to identify predictors of LS.ResultsWe included 1,127 patients with CVT. During a median follow-up of 2.0 years (interquartile range [IQR] 1.0–6.3), 123 patients (11%) experienced ≥1 LS…

AdultMaleStatus epilepticus030204 cardiovascular system & hematology03 medical and health sciencesEpilepsy0302 clinical medicineRecurrenceRisk FactorsSeizuresInterquartile rangemedicineHumansStrokeVenous ThrombosisIntracerebral hemorrhagebusiness.industryIncidenceHazard ratiocerebral venous thrombosisSymptomatic seizuresMiddle Agedmedicine.disease3. Good healthVenous thrombosisAnesthesiaFemaleSettore MED/26 - NeurologiaNeurology (clinical)Intracranial Thrombosismedicine.symptombusiness030217 neurology & neurosurgeryNeurology
researchProduct

Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behcet's disease and deep vein thrombosis

2004

OBJECTIVE: To evaluate the frequency and type of vascular lesions and to study the association of factor V gene G1691A (Leiden) and prothrombin gene G20210A polymorphisms with venous thrombosis in Italian patients with Behçet's disease (BD). METHODS: Included were 118 consecutive Italian BD patients followed over a 3-year period (1997-1999) who satisfied the International Study Group criteria for BD. The control group consisted of 132 healthy Italian blood donors. All BD patients and controls were genotyped by polymerase chain reaction and allele-specific restriction enzyme techniques for factor V Leiden and prothrombin gene G20210A polymorphisms. RESULTS: Vascular lesions were observed in …

AdultMaleVenous ThrombosisFactor V Leiden mutation Prothrombin G20210A mutationAdolescentGenotypeBehcet SyndromeFactor VMiddle AgedBehc ̧et’s disease; Deep vein thrombosis; Factor V Leiden mutation Prothrombin G20210A mutationAdolescent; Adult; Behcet Syndrome; Factor V; Female; Gene Frequency; Genotype; Humans; Italy; Male; Middle Aged; Prothrombin; Risk Factors; Venous Thrombosis; Point MutationGene FrequencyItalyDeep vein thrombosiRisk FactorsFactor V Leiden mutationHumansPoint MutationFemaleProthrombinProthrombin G20210A mutationBehcet’s disease
researchProduct

Deep venous thrombosis: Behaviour of the polymorphonuclear leukocyte integrin pattern at baseline and after in vitro activation

2005

In a group of 18 subjects with acute deep venous thrombosis (DVT), evidenced by clinical examination and echo-color-Doppler, we examined the phenotypical expression of the polymorphonuclear leukocyte (PMN) beta2-integrins (CD11a, CD11b, CD11c, CD18), obtained by using a flow cytofluorimeter. The evaluation was performed before and after in vitro activation (prolonged for 5 and 15 minutes) with 4-phorbol 12-myristate 13-acetate (PMA) and N-formyl-methionyl-leucyl-phenylalanine (fMLP). In DVT subjects, at baseline, the phenotypical expression of CD11b was decreased and that of CD11c was increased when compared with normal controls; no difference was found in CD11a and CD18 expression. In norm…

AdultMaleVenous ThrombosisIntegrinsSettore MED/09 - Medicina InternaCD11 AntigensNeutrophilsDeep venous thrombosis; polymorphonuclear leukocyte integrins; polymorphonuclear leukocyte activationMiddle AgedFlow CytometryNeutrophil ActivationDeep venous thrombosis polymorphonuclear leukocyte integrins polymorphonuclear leukocyte activationpolymorphonuclear leukocyte integrinsGene Expression RegulationCD18 AntigensCase-Control StudiesDeep venous thrombosisHumansTetradecanoylphorbol AcetateFemalepolymorphonuclear leukocyte activationAged
researchProduct

Distribution, genetic and cardiovascular determinants of FVIII:c - Data from the population-based Gutenberg Health Study

2015

Background: Elevated levels of FVIII:c are associated with risk for both venous and arterial thromboembolism. However, no population-based study on the sex-specific distribution and reference ranges of plasma FVIII: c and its cardiovascular determinants is available. Methods: FVIII:c was analyzed in a randomly selected sample of 2533 males and 2440 females from the Gutenberg Health Study in Germany. Multivariable regression analyses for FVIII:c were performed under adjustment for genetic determinants, cardiovascular risk factors and cardiovascular disease. Results and conclusions: Females (126.6% (95% CI: 125.2/128)) showed higher FVIII:c levels than males (121.2% (119.8/122.7)). FVIII:c le…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyLinkage disequilibriumGenotypeanimal diseasesPopulationFVIII:c reference valuesSingle-nucleotide polymorphismDiseaseAge DistributionVon Willebrand factorGermanyThromboembolismhemic and lymphatic diseasesInternal medicineVenous thrombosisHumansMedicineGenetic Predisposition to DiseaseProspective StudiesSex DistributioneducationAgededucation.field_of_studyEpidemiological studiesFactor VIIIPolymorphism Geneticbiologybusiness.industryIncidenceC-reactive proteinArterial thrombosisDNAMiddle AgedNomogrammedicine.diseaseVenous thrombosisPopulation SurveillanceImmunologybiology.proteinFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up Studies
researchProduct